Pharmaceuticals, Biotechnology and Life Sciences
ValiRx got patent from the US Patent and Trademark Office for modulators Of the SRC-kinase activity for preventing or treating…
ValiRx’s published study of VAL401, a single dose in an open-label trial of late-stage cancer patients, provide support for future studies of VAL401 as a cancer treatment, as the Cmaxdemonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.
ValiRx journey of bringing closer to market its leading anti-cancer therapeutic VAL201 for patients with hormone-sensitive and hormone-resistant prostate cancer, took a…
ValiRx’s has formed an Advisory Board to support its main board in new strategic guidance and technical advice.
Valisek, a joint venture between ValiRx, a clinical stage biotechnology company and Tangent Reprofiling Limited, plans to add a third clinical site, in Tbilisi, Georgia.
European Patent Office has granted ValiRx’s patent covering its major therapeutic compound VAL201, including prostate cancer, the pharmaceutical company said on…
ValiRx’s new cancer drug VAL401 progresses into the clinic